Plain Language Summaries of Publications for Patients
Find easy-to-understand summaries of Bayer’s oncology clinical trials, created by patients for patients. We believe in transparency and supporting your healthcare decisions. Here, you will find links to the original journal articles where these plain language summaries are published, making it simple for you to access clear and reliable information about research that matters to you. Our goal is to help you stay informed and empowered in your health journey.
Darolutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer: A Patient Perspective of the ARAMIS Trial
This Plain Language Summary presents the final results of the ARAMIS clinical trial, which evaluated the effects of darolutamide in men with non-metastatic castration-resistant prostate cancer (nmCRPC). The trial included
Co-written by a trial participant and a patient advocate, this summary makes complex clinical data accessible and meaningful for patients, caregivers, and the broader prostate cancer community. It reflects Bayer’s commitment to transparency, empowerment, and patient-centered care.
This summary is published as an Open Access article in Future Oncology. You can read the full Plain Language Summary below.
MA-M_DAR-ALL-0453
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer: A Patient and Caregiver Perspective and Plain Language Summary of the ARASENS Trial
This Plain Language Summary presents the results of the ARASENS clinical trial, which investigated whether adding darolutamide to standard treatment consisting of androgen deprivation therapy (ADT) and docetaxel could improve outcomes for men with metastatic hormone-sensitive prostate cancer (mHSPC).
The trial enrolled
The summary was co-developed by patients and caregivers to help make the findings more understandable and relevant to people affected by prostate cancer, including patients, families, and support communities.
This summary is published as an Open Access article in Future Oncology. You can read the full Plain Language Summary below.
MA-M_DAR-ALL-0453
The linked Plain Language Summaries are published as Open Access by Future Oncology and are freely available to the public. These summaries are intended to support patient understanding and engagement by presenting clinical trial data in accessible language. Bayer is not responsible for the content hosted on external publisher websites. Please refer to the original source for the most up-to-date and accurate information.